期刊文献+

特发性血小板减少性紫癜无效输注原因分析 被引量:3

Analysis of refractoriness to platelet transfusion in patients with idiopathic thrombocytopenic purpura
暂未订购
导出
摘要 目的:探讨特发性血小板减少性紫癜(ITP)患者血小板无效输注的原因。方法:90例确诊的ITP患者中对输注血小板的48例计算血小板计数增高指数(CCI),评价输注的效果并分析与感染、脾脏肿大、血小板抗体、骨髓巨核细胞数和免疫指标等因素的关系。结果:18例应用血小板和激素治疗的患者,44.4%有效输注,30例应用血小板、激素和丙种球蛋白患者,53.3%有效输注。24例无效输注患者中在感染组与非感染组、脾脏肿大组与正常组、血小板相关抗体升高组与正常组,有效输注率有显著性差异。骨髓巨核细胞数升高组与正常组、调节性T细胞低表达组与正常组,有效输注率差异无统计学意义。结论:ITP患者输注血小板50%存在无效输注,其原因可能与感染、脾脏肿大、血小板相关抗体有关。因此控制感染和抑制免疫应作为首选治疗,而血小板的输注应严格把握指征。 Objective:To study the reasons of refractoriness to platelet transfusion in patients with idiopathic thrombocytopenic purpura (ITP). Method: Among 90 ITP patients, 48 patients who received platelet transfusion were assessed the effect of transfusion by counting the corrected count increment (CCI) and then the relationship between the effective rate and the conditions or indexes of patients such as infection, splenomegaly, platelet associated antibody, megalokaryocytes amounts in bone marrow and regulatory T cells were also assessed. Result:44.4 % patients with ITP had efficient transfusions among 18 patients who received platelet transfusion and corticoste-folds, while 53.3 % effective rate was reached among 30 patients who received platelet transfusion, corticosteroids and immunoglobulin-G. Among 24 patients with ITP who were refractory to platelet transfusion, there was significant difference not only between infection group and non-infection group, but also between splenomegaly group and non-splenomegaly group, or between high-platelet associated antibody group and normal group. But there was no significant difference between low-regulatory T cells group and normal group, or between high-megalokaryocytes amounts group and normal group. Conclusion: 50% of ITP patients get refractoriness to platelet transfusion. The reasons perhaps include infection, splenomegaly and high level of platelet associated antibody. So the optimized therapy is to control the infections and suppress immunity at first, while the platelet transfusion should be used only when necessary.
出处 《临床血液学杂志》 CAS 2008年第4期347-349,共3页 Journal of Clinical Hematology
关键词 紫癜 血小板减少性 血小板 无效输注 Idiopathic thrombocytopenic purpura(ITP) Platelet Refractoriness of transfusion
  • 相关文献

参考文献8

  • 1PETZ L D, GARRATTY G, CALHOUN L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity[J]. Transfusion, 2000,40 : 1446 - 1456.
  • 2PANISTSAS F P, THEODOROPOULOU M, KOU RAKLIS A, et al. Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response[J]. Blood, 2004, 103: 2645-2647.
  • 3CATANIL L, MARIA E F,PIER L T, et al. Dendritic cells of immune thrombocytopenic purpura show increased capacity to present apoptotic platelet to T lymphocytes[J]. Experimental hematology, 2006,34 : 879-887.
  • 4DOUGLAS B C, JAMES B B. How I treat idiopathic thrombocytopenic purpura (ITP) [J]. Blood, 2005, 106:2244-2251.
  • 5李双,陈凤英,桂嵘,蒋铁斌,王小卫,朱碧娅,欧阳淑娟.临床血小板输注81例疗效分析[J].临床血液学杂志(输血与检验),2007,20(2):70-71. 被引量:2
  • 6瞿桂芳,吴涛.血液病患者血小板输注无效原因探讨及预防[J].中国冶金工业医学杂志,2006,23(4):442-444. 被引量:2
  • 7ANDERSSON P O, STOCKELBERG D, JACOBSSON S, et al. A transforming growth factor-betal-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenia purpura[J]. Ann Hematol, 2000,79 : 507 - 513.
  • 8尤建国,李玉峰,汪承亚.血小板输注无效及干预措施的研究进展[J].国际输血及血液学杂志,2006,29(6):499-502. 被引量:28

二级参考文献24

  • 1Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion, 2000,40 (12) : 1446-1456.
  • 2Goodnough LT, Kuter DJ, McCullough J, et al. Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin. Blood, 2001, 98(5) :1346-1351.
  • 3Kosugi S, Tomiyama Y, Honda S, et al. Platelet-associated anti-GP Ⅱb-Ⅲa autoantibodies in chronic immune thrombocytopenic purpura recognizing epitopes close to the ligand-binding site of glycoprotein (GP) Ⅱb. Blood, 2001,98(6):1819-1827.
  • 4Boylan B, Chen H, Rathore V, et al. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood, 2004,104(5): 1350-1355.
  • 5Fabris F, Soini B, Sartori R, et al. Clinical and laboratory factors that affect the post transfusion platelet increment. Transfus Sci,2000,23(1) :63-68.
  • 6Davoren A, Mcparland P, Crowley J, et al. Antenatal screening for human platelet antigen-la: results of a prospective study at a large maternity hospital in Ireland. BJOG,2003,110(5):492-496.
  • 7Kekomaki S, Volin L, Koistinen P, et al. Successful treatment of platelet transfusion refractoriness : the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia. EurJ Haematol,1998,60(2):112-118.
  • 8Killick SB, Win N, Marsh JC, et al. Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia. Br J Haematol, 1997,97(3):667-684.
  • 9Zhang X, Araki N, Ito K. Post-transfusion alloimmunization to granulocytes and platelets in Japanese patients as determined by the MPHA method. Transfus Apher Sci,2001,25(3):163-172.
  • 10Berry JE, Murphy CM, Smith GA, et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol, 2000,110(3) : 735-742.

共引文献29

同被引文献13

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部